BR9916197A - Método para o tratamento de isquemia cerebral e uso de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral - Google Patents

Método para o tratamento de isquemia cerebral e uso de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral

Info

Publication number
BR9916197A
BR9916197A BR9916197-4A BR9916197A BR9916197A BR 9916197 A BR9916197 A BR 9916197A BR 9916197 A BR9916197 A BR 9916197A BR 9916197 A BR9916197 A BR 9916197A
Authority
BR
Brazil
Prior art keywords
cerebral ischemia
treatment
erythropoietin
derivatives
brain tissue
Prior art date
Application number
BR9916197-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Hannelore Ehrenreich
Christoph Gleiter
Original Assignee
Hannelore Ehrenreich
Christoph Gleiter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7891015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9916197(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hannelore Ehrenreich, Christoph Gleiter filed Critical Hannelore Ehrenreich
Publication of BR9916197A publication Critical patent/BR9916197A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
BR9916197-4A 1998-12-14 1999-12-13 Método para o tratamento de isquemia cerebral e uso de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral BR9916197A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19857609A DE19857609A1 (de) 1998-12-14 1998-12-14 Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
PCT/EP1999/009864 WO2000035475A2 (de) 1998-12-14 1999-12-13 Verfahren zur behandlung von cerebralen ischämien sowie verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien

Publications (1)

Publication Number Publication Date
BR9916197A true BR9916197A (pt) 2001-09-04

Family

ID=7891015

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916197-4A BR9916197A (pt) 1998-12-14 1999-12-13 Método para o tratamento de isquemia cerebral e uso de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral

Country Status (26)

Country Link
US (1) US7514072B1 (https=)
EP (1) EP1140139B2 (https=)
JP (2) JP4750947B2 (https=)
KR (1) KR100774827B1 (https=)
CN (1) CN1187085C (https=)
AT (1) ATE253932T1 (https=)
AU (1) AU766216C (https=)
BG (1) BG65417B1 (https=)
BR (1) BR9916197A (https=)
CA (1) CA2353553C (https=)
DE (2) DE19857609A1 (https=)
DK (1) DK1140139T4 (https=)
ES (1) ES2211218T5 (https=)
HK (1) HK1042655B (https=)
HU (1) HUP0104709A3 (https=)
ID (1) ID29107A (https=)
IL (2) IL143579A0 (https=)
MX (1) MXPA01005971A (https=)
NO (1) NO330079B1 (https=)
NZ (1) NZ541591A (https=)
PL (1) PL202483B1 (https=)
PT (1) PT1140139E (https=)
RO (1) RO121409B1 (https=)
RU (1) RU2242991C2 (https=)
WO (1) WO2000035475A2 (https=)
ZA (1) ZA200104626B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
KR101012932B1 (ko) * 1999-04-13 2011-02-08 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
DE10043457A1 (de) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
AR036400A1 (es) 2001-08-30 2004-09-08 Stem Cell Therapeutics Inc Regulacion combinada de la produccion de celulas nerviosas.
ATE541921T1 (de) 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
US7439063B2 (en) * 2002-06-11 2008-10-21 Burnham Institute For Medical Research Neuroprotective synergy of erythropoietin and insulin-like growth factors
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
EP1633383A4 (en) * 2003-03-27 2008-05-21 Janssen Pharmaceutica Nv USE OF ERYTHROPOIETIN FOR RE-ESTABLISHMENT FOLLOWING A CEREBRAL ISCHEMIC ACCIDENT
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
WO2005032467A2 (en) 2003-09-29 2005-04-14 Warren Pharmaceuticals, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
UA82561C2 (uk) * 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
CA2556266A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
CA2622758A1 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
WO2007036033A1 (en) * 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
WO2007106987A1 (en) * 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
BRPI0712063A2 (pt) * 2006-06-07 2011-12-20 Chugai Pharmaceutical Co Ltd tratamento de doenças isquêmicas usando eritropoietina
SI2170279T1 (en) * 2007-07-31 2018-04-30 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
RU2446834C2 (ru) * 2010-06-15 2012-04-10 Елена Александровна Лебедева Способ лечения пострадавших с сочетанной черепно-мозговой травмой
WO2012148200A2 (ko) 2011-04-26 2012-11-01 아주대학교 산학협력단 허혈성 혈관 질환 치료시술 보조용 조성물
RU2495688C1 (ru) * 2012-03-28 2013-10-20 Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" Способ лечения ишемии головного мозга в эксперименте
US9610444B2 (en) 2013-03-15 2017-04-04 Pacesetter, Inc. Erythropoeitin production by electrical stimulation
KR20190052855A (ko) 2017-11-09 2019-05-17 대한제당 주식회사 페길레이션된 에리스로포이에틴을 포함하는 허혈성 뇌질환 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
EP0945515A3 (en) 1989-11-06 2002-08-21 Cell Genesys, Inc. Production of proteins using homologous recombination
ES2151463T5 (es) 1989-12-22 2012-10-29 Merck Serono Sa Constructos de ADN para la activación y la modificación de la expresión de genes endógenos
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
JP3537151B2 (ja) 1991-12-26 2004-06-14 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
RU2068268C1 (ru) * 1992-03-19 1996-10-27 Учебно-научный центр Медицинского центра при Правительстве РФ Способ профилактики церебро-васкулярных заболеваний
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
BR9406490A (pt) 1993-04-29 1996-03-05 Abbott Lab Análogo de eritropoietina humana,DNA de filamento duplo,vetor de expressão célula de mamiferos em cultura composição farmaceutica segundo e terceiro análogo de eritropoietina humana e processos para fabricar um segundo análogo de eritropoietina e para usar um segundo análogo
CN1057534C (zh) 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
SE520730C2 (sv) 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
KR101012932B1 (ko) 1999-04-13 2011-02-08 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

Also Published As

Publication number Publication date
BG105575A (en) 2002-01-31
AU2283100A (en) 2000-07-03
HK1042655A1 (en) 2002-08-23
DK1140139T4 (da) 2009-06-08
WO2000035475A2 (de) 2000-06-22
KR20010082346A (ko) 2001-08-29
ES2211218T3 (es) 2004-07-01
NO20012896D0 (no) 2001-06-12
DE59907752D1 (de) 2003-12-18
PL349335A1 (en) 2002-07-15
PL202483B1 (pl) 2009-06-30
ES2211218T5 (es) 2009-06-03
WO2000035475A3 (de) 2000-10-19
JP4750947B2 (ja) 2011-08-17
EP1140139A2 (de) 2001-10-10
IL143579A0 (en) 2002-04-21
AU766216C (en) 2004-11-11
HUP0104709A2 (hu) 2002-04-29
NO330079B1 (no) 2011-02-14
HUP0104709A3 (en) 2002-05-28
KR100774827B1 (ko) 2007-11-07
CA2353553C (en) 2011-05-17
NZ541591A (en) 2007-08-31
EP1140139B1 (de) 2003-11-12
CN1187085C (zh) 2005-02-02
NO20012896L (no) 2001-08-14
HK1042655B (zh) 2005-09-23
JP2011079860A (ja) 2011-04-21
DE19857609A1 (de) 2000-06-15
MXPA01005971A (es) 2002-03-27
PT1140139E (pt) 2004-04-30
RU2242991C2 (ru) 2004-12-27
ZA200104626B (en) 2002-09-06
CN1335776A (zh) 2002-02-13
ATE253932T1 (de) 2003-11-15
US7514072B1 (en) 2009-04-07
RO121409B1 (ro) 2007-05-30
CA2353553A1 (en) 2000-06-22
AU766216B2 (en) 2003-10-09
JP2002532432A (ja) 2002-10-02
EP1140139B9 (de) 2004-03-31
BG65417B1 (bg) 2008-07-31
EP1140139B2 (de) 2009-03-18
IL143579A (en) 2007-10-31
ID29107A (id) 2001-07-26
DK1140139T3 (da) 2004-03-15

Similar Documents

Publication Publication Date Title
BR9916197A (pt) Método para o tratamento de isquemia cerebral e uso de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral
BR0010113A (pt) Preparações para uso externo na pele
BR9913288A (pt) Composição antioxidante compreendendo acetil l-carnitina e ácido alfa-lipóico
BR0013540A (pt) Formulações farmacêuticas e seu uso na prevenção de acidente vascular cerebral, diabetes e/ou falha de coração congestiva
BR9912098A (pt) Derivado de tiobenzimidazol, composição farmacêutica, e, agente preventivo e/ou terapêutico
BRPI0009956A (pt) composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e betametasona, e, uso da mesma
BR9815442A (pt) Liberação terapêutica dirigida de compostos de vitamina d
SG49625A1 (en) Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
BR9911072A (pt) Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépicos e/ou agentes promotores da cura de feridas no trato respiratório inferior
BRPI0520588B8 (pt) uso de composições farmacêuticas para o tratamento de doenças do ouvido interno
BR0209523A (pt) Utilização de um antioxidante para a fabricação de um medicamento destinado ao tratamento e/ou à prevenção dos distúrbios oculares de superfìcie
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
BR9910553A (pt) Composição de liberação prolongada, processo para produção da mesma, produto de liberação prolongada, formulação farmacêutica, e, processo para tratamento de uma indicação, de um distúrbio e uma inflamação
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BR0312845A (pt) Tetratiomolibdato de tetrapropilamÈnio e compostos relacionados para terapias antiangiogênicas
ES2153906T3 (es) Uso de incienso para el tratamiento de la enfermedad de alzheimer.
BRPI0408829A (pt) uso de eritropoietina em recuperação de acidente vascular cerebral
BR0210744A (pt) Combinação farmacêutica sinergìstica para a prevenção ou tratamento de diabetes
BRPI0414139A (pt) métodos e composições para tratar infecções por herpes
BR9912703A (pt) Composição antioxidante, antiprolìfera, compreendendo uma carnitina e um carotenóide
BRPI0407140A (pt) Droga terapêutica para vìrus
BR9712614A (pt) Composição farmacêutica,processos para aumentar e manter a homogeneidade de uma composição farmac&eutica,para tratar,reverter,reduzir ou inibir infeccões retrovirais e para preparação de uma composição farmacêutica,uso de lamivudina ou de um derivado farmaceuticamenete aceitável da mesma,de zidovudina,ou de um derivado farmaceuticamente aceitável da mesma e de um agente de deslizamento farmaceuticamente aceitável,e, artigo de amnufatura.
BR0212167A (pt) Forma de dosagem oral de liberação prolongada, uso da mesma, método para a prevenção e/ou tratamento de distúrbios e perturbações médicas, e, processo para a fabricação de uma forma de dosagem de liberação prolongada
BR0009676A (pt) Método para o tratamento e/ou profilaxia de malária, usos de atovaquona e de uma combinação de atovaquona, proguanila e primaquina, combinação de atovaquona, proguanila e primaquina, kit, e, formulação farmacêutica
WO2000015207A3 (en) Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s)

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10 (VIII) E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.